輝瑞疫苗失效？以色列完全接種者感染變異毒株
Sy Mukherjee
2021-07-01
由于此前在完全接種了輝瑞公司（Pfizer）新冠疫苗的成年人中出現(xiàn)了少量新冠病毒變異的陽性病例，以色列衛(wèi)生部官員將重啟室內(nèi)口罩令。普遍意義上的完全接種新冠疫苗是指已經(jīng)接種了兩針疫苗，并且距離第二針接種已經(jīng)過去了兩周。
德爾塔變異毒株已經(jīng)迅速成為新冠肺炎病例在印度和英國(guó)等某些國(guó)家的疫情主要來源。在美國(guó)的新病例中也占了越來越多的份額，主要集中在疫苗接種率低的州。這種突變最初在印度發(fā)現(xiàn)，似乎比新型冠狀病毒的傳播性強(qiáng)得多，可能對(duì)年輕人構(gòu)成特別威脅。
據(jù)《華爾街日?qǐng)?bào)》（Wall Street Journal）報(bào)道，以色列政府的疫情研究專家預(yù)計(jì)，以色列約90%的新病例將與德爾塔變異毒株有關(guān)。在專家檢測(cè)的感染德爾塔變異毒株的病例中，約有一半發(fā)生在16歲以下未接種疫苗的兒童中。但在此次疫情中感染的成年人里，約有一半已經(jīng)接種了新冠疫苗。
不過現(xiàn)在還不是草木皆兵的時(shí)候。早期的研究表明，在德爾塔變異毒株肆虐的英國(guó)，輝瑞疫苗在完全免疫的人群中，預(yù)防住院患者感染德爾塔變異毒株方面，有效率達(dá)到96%。據(jù)以色列政府的新冠疫情研究專家蘭?巴利塞說：“在過去五天里，以色列只記錄了5例新冠肺炎重癥病例。當(dāng)然，病例數(shù)、住院人數(shù)（以及死亡人數(shù)）這些數(shù)據(jù)都相對(duì)滯后。輝瑞疫苗在預(yù)防感染新冠肺炎德爾塔變異毒株方面是否有效，或者是否需要注射加強(qiáng)針來預(yù)防，這些問題還需要時(shí)間來檢驗(yàn)。”
輝瑞公司對(duì)其疫苗對(duì)抗德爾塔變異毒株的有效性充滿信心。據(jù)路透社（Reuters）報(bào)道，輝瑞公司的以色列醫(yī)療主任阿隆?拉帕波特對(duì)以色列當(dāng)?shù)仉娨暸_(tái)表示：“我們今天積累的數(shù)據(jù)源于我們?cè)趯?shí)驗(yàn)室進(jìn)行的研究，包括來自印度德爾塔變異毒株取代英國(guó)變種成為常見病毒變種的數(shù)據(jù)，表明我們的疫苗對(duì)預(yù)防新冠肺炎的有效率約90%。”
簡(jiǎn)而言之，至少還需要幾個(gè)月的時(shí)間才能夠了解現(xiàn)有的新冠疫苗對(duì)德爾塔變異毒株起到何種作用。（財(cái)富中文網(wǎng)）
編譯：於欣
由于此前在完全接種了輝瑞公司（Pfizer）新冠疫苗的成年人中出現(xiàn)了少量新冠病毒變異的陽性病例，以色列衛(wèi)生部官員將重啟室內(nèi)口罩令。普遍意義上的完全接種新冠疫苗是指已經(jīng)接種了兩針疫苗，并且距離第二針接種已經(jīng)過去了兩周。
德爾塔變異毒株已經(jīng)迅速成為新冠肺炎病例在印度和英國(guó)等某些國(guó)家的疫情主要來源。在美國(guó)的新病例中也占了越來越多的份額，主要集中在疫苗接種率低的州。這種突變最初在印度發(fā)現(xiàn)，似乎比新型冠狀病毒的傳播性強(qiáng)得多，可能對(duì)年輕人構(gòu)成特別威脅。
據(jù)《華爾街日?qǐng)?bào)》（Wall Street Journal）報(bào)道，以色列政府的疫情研究專家預(yù)計(jì)，以色列約90%的新病例將與德爾塔變異毒株有關(guān)。在專家檢測(cè)的感染德爾塔變異毒株的病例中，約有一半發(fā)生在16歲以下未接種疫苗的兒童中。但在此次疫情中感染的成年人里，約有一半已經(jīng)接種了新冠疫苗。
不過現(xiàn)在還不是草木皆兵的時(shí)候。早期的研究表明，在德爾塔變異毒株肆虐的英國(guó)，輝瑞疫苗在完全免疫的人群中，預(yù)防住院患者感染德爾塔變異毒株方面，有效率達(dá)到96%。據(jù)以色列政府的新冠疫情研究專家蘭?巴利塞說：“在過去五天里，以色列只記錄了5例新冠肺炎重癥病例。當(dāng)然，病例數(shù)、住院人數(shù)（以及死亡人數(shù)）這些數(shù)據(jù)都相對(duì)滯后。輝瑞疫苗在預(yù)防感染新冠肺炎德爾塔變異毒株方面是否有效，或者是否需要注射加強(qiáng)針來預(yù)防，這些問題還需要時(shí)間來檢驗(yàn)。”
輝瑞公司對(duì)其疫苗對(duì)抗德爾塔變異毒株的有效性充滿信心。據(jù)路透社（Reuters）報(bào)道，輝瑞公司的以色列醫(yī)療主任阿隆?拉帕波特對(duì)以色列當(dāng)?shù)仉娨暸_(tái)表示：“我們今天積累的數(shù)據(jù)源于我們?cè)趯?shí)驗(yàn)室進(jìn)行的研究，包括來自印度德爾塔變異毒株取代英國(guó)變種成為常見病毒變種的數(shù)據(jù)，表明我們的疫苗對(duì)預(yù)防新冠肺炎的有效率約90%。”
簡(jiǎn)而言之，至少還需要幾個(gè)月的時(shí)間才能夠了解現(xiàn)有的新冠疫苗對(duì)德爾塔變異毒株起到何種作用。（財(cái)富中文網(wǎng)）
編譯：於欣
Israeli health officials are returning to mask mandates at indoor facilities following a small spate of positive COVID Delta variant cases in adults who had been fully vaccinated with Pfizer's coronavirus vaccine. That is, these adults had received two doses of the vaccine, and it had been two weeks since their second dose, the generally accepted timeline for full vaccination.
The Delta variant has rapidly become the main source of new COVID cases in certain parts of the globe including India and the U.K. It also makes up an increasing share of new cases in the U.S., clustered in states with low vaccination rates. The mutation, originally identified in India, appears to be far more transmissible than the novel coronavirus and could be a particular threat to younger people.
In Israel, expert advisers to the government estimate that about 90% of new cases are linked to the Delta variant, according to the Wall Street Journal. About half of the Delta variant cases examined by experts occurred in children under the age of 16 who haven’t been vaccinated. But about half of adults who were infected in this outbreak were fully immunized with the COVID vaccine.
That doesn’t mean it’s time to panic quite yet. Early studies in the U.K., where the Delta variant is also prominent, have suggested that the Pfizer vaccine in fully immunized people is 96% effective at preventing hospitalizations for those who become infected with the Delta variant. And in the past five days, Israel has recorded only five severe cases of COVID, according to Ran Balicer, a COVID adviser to the Israeli government. Of course, illness and hospitalizations (and deaths) are all lagging indicators. It will take more time to tell just how effective Pfizer's vaccine is at preventing debilitating COVID illness in those with the Delta variant, or whether booster shots will be required to address it.
Pfizer is sounding a confident note in its vaccine's efficacy against the strain. “The data we have today, accumulating from research we are conducting at the lab and including data from those places where the Indian variant, Delta, has replaced the British variant as the common variant, point to our vaccine being very effective, around 90%, in preventing the coronavirus disease, COVID-19,” Pfizer’s Israel medical director Alon Rappaport told a local Israeli station, according to Reuters.
In short：It’s going to take at least a few more months to get a better grasp of the relationship between available COVID vaccines and the Delta variant.
財(cái)富中文網(wǎng)所刊載內(nèi)容之知識(shí)產(chǎn)權(quán)為財(cái)富媒體知識(shí)產(chǎn)權(quán)有限公司及/或相關(guān)權(quán)利人專屬所有或持有。未經(jīng)許可，禁止進(jìn)行轉(zhuǎn)載、摘編、復(fù)制及建立鏡像等任何使用。
